Surrozen reports Q1 2022 results; Phase 1 trials on track for Q3

Surrozen, Inc./DE

2023-Q1 EPS reported -$0.23

Q1 financial results announced; no specific revenue or loss figures in the press release excerpt.
On track to initiate Phase 1 trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) in Q3 2022.
Presented preclinical data for SZN-413 (retinal vascular diseases) at ARVO showing Wnt activation and vessel regrowth.
Preclinical data for lacrimal gland and lung Wnt modulation highlighted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.